Safety of perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: An interim safety analysis of the DANTE, a randomized, open-label phase II trial of the German Gastric Group at the AIO and the SAKK.
Salah‐Eddin Al‐Batran(Goethe University Frankfurt), Nils Homann(Fraunhofer Project Centre Wolfsburg), Eray Goekkurt(Sorbonne Université), Andreas Wicki(University Hospital of Basel), Jonathan Talbot(Roche (Switzerland)), Ekkehard Eigendorff(Jena University Hospital), Claus Bolling(Agaplesion Markus Hospital), Ralf‐Dieter Hofheinz(University of Mannheim), Christin Pink(Helios Hospital Bad Saarow), Lisa Waberer(Krankenhaus Nordwest), Harald Schmalenberg(Heidelberg University), Thomas J. Ettrich(Universität Ulm), Thorsten Oliver Goetze(Institute of Clinical Cancer Research), Peter Thuss‐Patience(Charité - Universitätsmedizin Berlin), Stefan Angermeier(Klinikum Ludwigsburg), Michael Schenk(Krankenhaus Barmherzige Brüder), Albrecht Kretzschmar(Roche (Switzerland)), Sylvie Lorenzen(Technical University of Munich), Alexander Rheinhard Siebenhuener, Claudia Pauligk(Goethe University Frankfurt)
Cited by 6
Related Papers
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k